Obesity is a major health problem over the worldwide. Bariatric and metabolic surgery remain the best efficient way for the treatment of obesity and the metabolic syndrome. The single anastomosis sleeve ileal (SASI) bypass is a novel bariatric procedure proposed to manage this condition. This study aims to review the efficacy and safety of SASI bypass on comorbidity associated to obesity. Background metabolic surgery; bariatric surgery; morbid obesity. Methods and patients We searched Cochrane Library, Pubmed and Embase up to January 2021. We enrolled in this review 15 case series. Summary In this study,1463 patients were enrolled. Mean age was varied between 30,7 and 53,4 years and initial mean body mass index (BMI) was varied between 35,05 and 58,3 kg/m2. A total of 692 patients (53.23%) have type 2 diabetes mellitus (T2DM). The percentage of remission of T2DM of all patients who completed the 1-year follow-up is 89.9%. Concerning dyslipilemia, gastroesophageal reflux diseases (GERD) and Hypertension, the percentage were 75%, 91.77% and 44.78% respectively. SASI bypass was associated with minor postoperative nutritional complications. The major side effect reported on postoperative was abdominal bleeding. Conclusion SASI bypass is an effective and safe bariatric surgical procedure that achieves satisfactory weight loss with significantly improvement in obesity-related complications, such as T2DM and GERD, and minimal postoperative nutritional complications.
Full Text via ClinicalKey